This is a news story, published by Yahoo Finance, that relates primarily to Eli Lilly news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
loss drug Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest diabetes risks news, diabetes news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Blockbuster Drug Pressures Growth OutlookInvestopedia
•80% Informative
Shares of Insulet and DexCom were the weakest-performing S&P 500 stocks on Tuesday .
A study showed that a popular drug made by Eli Lilly significantly lowers the risk of developing type 2 diabetes.
The losses for the medtech stocks came after Eli Lilly said its blockbuster drug effectively reduced the risk.
The results could be a concern for companies that make products to treat related conditions.
VR Score
82
Informative language
86
Neutral language
79
Article tone
formal
Language
English
Language complexity
66
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
1
Affiliate links
no affiliate links